Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants.

Human vaccines & immunotherapeutics

PubMedID: 28857649

Church JA, Rukobo S, Govha M, Carmolli MP, Diehl SA, Chasekwa B, Ntozini R, Mutasa K, Humphrey JH, Kirkpatrick BD, Prendergast AJ. Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants. Hum Vaccin Immunother. 2017;0.
It remains uncertain whether HIV-exposed uninfected (HEU) infants have impaired responses to oral vaccines. We carried out a cross-sectional study of 6-month-old infants recruited at birth to the ZVITAMBO trial in Zimbabwe between 1997-2001, prior to introduction of prevention of mother-to-child transmission interventions. We measured poliovirus-specific IgA to type 1-3 polio strains by semi-quantitative capture ELISA in cryopreserved serum samples collected from 85 HEU and 101 HIV-unexposed infants at 6 months of age, one month after their last immunisation with trivalent OPV. Almost all infants were breastfed, with the majority in both groups mixed breastfed (70. 6% HEU versus 71. 3% HIV-unexposed). Median (IQR) vaccine titres for HEU and HIV-unexposed infants were 1592 (618-4896) versus 1774 (711-5431) for Sabin 1 (P = 0. 46); 1895 (810-4398) versus 2308 (1081-4283) for Sabin 2 (P = 0. 52); and 1798 (774-4192) versus 2260 (996-5723) for Sabin 3 (P = 0. 18). There were no significant differences in vaccine titres between HEU and HIV-unexposed infants, suggesting that vertical HIV exposure does not impact oral poliovirus vaccine immunogenicity.